Comprehensive biomarker testing can play an important role in the personalized treatment for patients with non-small cell lung cancer (NSCLC).
In honor of Lung Cancer Awareness Month 2021, the Association of Community Cancer Centers (ACCC) and Amgen co-hosted a live discussion with a panel of multidisciplinary oncology experts, focusing on the hurdles cancer care teams face when implementing biomarker testing for patients and what can be done to ease these burdens The panelists explored the treatment landscape of NSCLC, the importance of comprehensive biomarker testing to inform decision-making, and effective practices on how to incorporate biomarker testing into your cancer program.
Watch the full-length panel discussion which originally aired live on November 1, 2021.
These short video segments from the full-length panel discussion provide concise and informative learning when time is limited. Hear insights in relation to specific aspects of biomarker testing for patients with non-small cell lung cancer.
What is comprehensive biomarker testing?
Why is it important for patients with lung cancer to receive biomarker testing?
Who should receive lung cancer biomarker testing and when do we test?
A multidisciplinary approach to comprehensive biomarker testing
Tips for establishing institutional policies and procedures for comprehensive biomarker testing
Tips on how to communicate with patients and caregivers about comprehensive biomarker testing
Comprehensive biomarker testing: The role of the oncologist
Comprehensive biomarker testing: The role of the pathologist
Comprehensive biomarker testing: The role of the nurse navigator
Comprehensive biomarker testing: The role of the pulmonologist
The Biomarker Testing Implementation Roadmap for Advanced Non-Small Cell Lung Cancer (NSCLC)
Is there an age limit for lung cancer biomarker testing?